ArticleCureus2026
Antimitochondrial Antibody-Negative Primary Biliary Cholangitis: A Diagnostic Challenge in a Sri Lankan Patient.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary biliary cholangitis (PBC) is a chronic autoimmune cholestatic liver disease characterized by progressive destruction of small intrahepatic bile ducts, in which antimitochondrial antibodies (AMA) are detected in the majority of patients and serve as a key diagnostic marker. A small subset of patients, however, remains AMA-negative, creating diagnostic uncertainty and potentially delaying treatment. We report the case of a 65-year-old woman who presented with progressive pruritus and fatigue and was found to have a predominantly cholestatic liver enzyme pattern. Extensive evaluation excluded extrahepatic biliary obstruction, viral hepatitis, and drug-induced liver injury. Despite a negative AMA test, a liver biopsy demonstrated portal inflammatory infiltrates with interface hepatitis and a prominent bile ductular reaction, establishing the diagnosis of AMA-negative PBC. The patient was commenced on ursodeoxycholic acid with partial symptomatic improvement. This case highlights the importance of maintaining clinical suspicion for PBC despite negative AMA and underscores the diagnostic value of liver biopsy in seronegative cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.